COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey

Patients and methods

The present study was a cross-sectional, random telephonic survey conducted from 20^th April to 20^th July 2020 on patients with rheumatological disorders, under long-term follow-up at the Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India, and residing in Delhi-NCR (hot spot for COVID19), India. Telephonic method was chosen because of ongoing lockdown and consequent travel restrictions limiting physical access to patients. The study protocol was reviewed and approved by the institutional review board (no. IEC-280/17.4.2020).

Inclusion criteria were: adult patients (>18 years of age) with a definite rheumatic disease diagnosed by a physician and under regular follow up at our Department for more than 1 year. Patients were telephonically contacted and a verbal consent was obtained. Patient data were extracted based on a predesigned proforma which included demographic details, disease duration, current disease status, medication details (details of csDMARDs, tsDMARDs and monoclonal antibodies); travel history (within and outside India); symptoms suggestive of COVID-19 (flu-like symptoms and others with leading questions for anosmia, dysgeusia, red eyes, skin rashes, shortness of breath and dry cough), status of COVID-19 test (whether a nasopharyngeal swab was done or not); history of contact with a COVID 19 positive case and need for hospital admission and course of hospital treatment; and status of rheumatic disease during the period of study. In certain cases, especially in patients with reported increased disease activity, or those who were COVID19 positive, were contacted multiple times throughout the period to ensure the correct clinical course of both COVID-19 and the underlying rheumatic disease.

Statistical methods

Descriptive data was displayed as mean ± standard deviation and categorical data as percentage (fraction). Comparison of means was done with Mann Whitney U test and comparison of proportions with Fisher’s exact test or Chi Squared test, as appropriate. Incidence of COVID-19 was expressed as percentage with 95% confidence interval (CI). For comparison of incidences across different diagnostic classes, to correct for family wise error rate, correction of p-value divided by number of pre-defined comparisons was taken as cut-off. All statistical calculations were done using Microsoft Excel Spreadsheets and SPSS ver 20 (IBM Corp.).

Description of the cohort

Overall, 900 patients were contacted and 840 patients responded. The mean age was 45 ± 13 years with 54% females (n=456). Detailed demographic and clinical details of the cohort is given in Table 1. Majority of the patients had rheumatoid arthritis (RA) (85%, 713/840) followed by systemic lupus erythematosus (SLE) (12%, 100/840) and others had the following diagnoses: ankylosing spondylitis (AS) (n=14), psoriatic arthritis (PsA) (n=6), scleroderma (SSc) (n=3), Sjogren syndrome (SjS) (n=3) and dermatomyositis (n=1). Mean duration of disease was 11.3 ± 6.3 years. Overall, 78% (656/840) were on at least one of prednisolone, csDMARDs, tsDMARDs or on monoclonal antibodies and the rest 184 (22%) patients were only on hydroxychloroquine. Mean doses of the drugs were as follows: prednisolone 5.1 ± 1 mg/day; hydroxychloroquine 321 ± 73 mg/day; methotrexate 18.8 ± 4.3 mg/week; leflunomide 17.4 ± 4 mg/day; sulfasalazine 1.8 ± 0.6 gm/day; mycophenolate mofetil 2000 mg/day and azathioprine 100 mg/day. Approximately one third patients (36%, 302/840) had at least one comorbidity. Fifty-two patients (6%) had ≥2 comorbidities. Sixteen patients reported stoppage of medications because of the fear of contracting the infection or difficulty in procuring drug due to lockdown in India: hydroxychloroquine in nine, methotrexate in four, leflunomide in two and prednisolone, infliximab and tocilizumab in one each. Eleven percent (11/100) of SLE patients reported increased disease activity and 17% (121/713) patient with RA reported increased joint symptoms. Among the 11 lupus disease flares, one was renal, five haematological, two musculoskeletal and three were cutaneous.

COVID-19 cases

Among our patients 29 reported flu-like symptoms but rT-PCR on nasophayngeal swab was done only on six cases (four with RA, one with AS, and one with SLE) among which four tested positive and the rest didn’t report to the medical facility. Detailed demographic and clinical features of COVID-19 positive cases is given in Table 2. None of the patients were on tsDMARDs or monoclonal antibodies. Two had hypertension and one had coronary artery disease as comorbidities. All of them were admitted in Government run medical institutions with fever. None of the patients required intensive care or ventilatory support. All were discharged without any complications. All of these patients temporarily discontinued their rheumatological drugs, except hydroxychloroquine. After recovery from COVID-19, one patient with RA had a disease flare which resolved with institution of DMARDs.

The incidence of confirmed COVID-19 in our cohort was 0.476% (95% CI 0.19-1.22). The background general population living in Delhi during this period is 21777954, [7] and number of COVID-19 cases in Delhi during the study period was 113193, [8] giving incidence of 0.519% (95% CI: 0.517-0.523). The incidence of COVID-19 was similar to general Delhi population (0.476% vs 0.519%, difference 0.043%, 95% CI: −0.69 to 0.33, p=0.86). Incidence of COVID-19 cases was asymmetrically distributed among different diagnostic classes (Figure 1). If we consider only the diagnostic class of RA, even then the incidence of COVID-19 was similar between patients with RA and the general Delhi population (0.56% vs 0.519%, difference 0.041%, 95% CI: −0.3012% to 0.9131%, p=0.87).

COVID-19: clinically suspected cases

Another 25 patients, had flu-like symptoms but were not tested with nasopharyngeal swab. None of these patients reported travel outside India or Delhi or even contact with a known COVID-19 case. Details of these patients are summarized in Table 1. However, all of them resided within containment zones, which are zones demarcated by the Government as high risk of transmission and have strong restriction of movement. Twenty-one of them had RA, three had SLE and one had AS. Among these patients, seventeen were on methotrexate, eleven were on leflunomide, ten were on hydroxychloroquine, seven were on prednisolone, three on sulfasalazine, two on anti-TNF agents and one each on azathioprine, mycophenolate and rituximab. Only one of these patients was hospitalized and needed supplemental oxygen but made a full recovery. The incidence of Flu-like symptoms in patients with RA was similar to those observed in CTD (2.95%, 21/713 vs 2.8%, 3/107 respectively, p=0.999) and patients with SpA (2.95%, 21/713 vs 5%, 1/20, respectively, p=0.46).

Two patients with RA had stopped medications and both of them and four other patients with RA experienced a disease relapse, all of them after the flu-like episode. One patient with SLE also discontinued all her medications following her flu-like episode and developed a renal flare with subnephrotic proteinuria and raised creatinine for which she was instituted on high dose prednisolone and mycophenolate and is still in re-induction therapy.

Conflicts of interest/Competing interests:

none to declare